

News Release

January 18, 2016
Galderma Pharma S.A.
Maruho Co., Ltd.

Maruho and Galderma to Join Forces in a Strategic Alliance in Japan

Lausanne (Switzerland) - Osaka (Japan), January 18, 2016 – Maruho Co., Ltd. (“Maruho”, Headquarters: Osaka, Japan, President and CEO: Koichi Takagi), and Galderma Pharma S.A. (“Galderma”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman), two leading dermatology companies, today announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea.

“This alliance with Galderma allows Maruho to further promote its aim to make an outstanding contribution in the dermatology area in Japan” said Koichi Takagi, President and CEO of Maruho.

“As a global leader in dermatology, Galderma is committed to meeting the needs of patients by providing medical solutions for physicians all around the world. The partnership between Galderma and Maruho is a key milestone in our mission to increase access to Galderma’s innovative therapies in Japan, and elevate patient care” said Stuart Raetzman, Chief Executive Officer of Galderma Pharma S.A.

Outline of the Agreements

Under the terms of the agreements, from July 17, 2016, Maruho will market Differin Gel 0.1%, Galderma’s acne vulgaris treatment agent. Maruho will also market the acne vulgaris treatment marketed overseas as Epiduo, currently filed for approval in Japan. Additionally, Maruho will be responsible for the development and commercialisation in Japan of Galderma’s topical therapeutic agent for the erythema associated with rosacea, marketed as Mirvaso globally, and scalp psoriasis treatment marketed overseas as Clobex. These



products are leading medical solutions developed by Galderma globally and are already approved and commercialised in many countries around the world.

Additionally, Maruho has the right of first evaluation for other innovative prescription medical solutions coming from Galderma's pipeline with the intention to be developed for the Japanese market.

By strengthening its pipeline of innovation and its portfolio of therapeutic agents, for acne and rosacea in particular, Maruho will be providing new treatment options to dermatologists and healthcare professionals as part of its commitment to meeting the needs of patients suffering from skin diseases in Japan.



About MIRVASO®

MIRVASO is a topical gel formulation therapeutic agent containing brimonidine 0.33%, indicated for the treatment of erythema associated with rosacea. After receiving approval in the US in August 2013, it is marketed in more than 30 countries.

About EPIDUO®

EPIDUO is a gel formulation of a combination drug indicated for the treatment of acne vulgaris containing 2.5% benzoyl peroxide and 0.1% adapalene. It was filed for approval in Japan in June 2015. In the US it was approved in 2008 and launched in 2009. In France it was approved and launched in 2008 and is used widely in the western countries.

About CLOBEX®

CLOBEX is a topical treatment containing clobetasol propionate 0.05%. It is indicated for the topical treatment of moderate to severe plaque psoriasis in adults in the US. It was approved in the US in 2004 and is currently marketed in more than 50 countries.

About Galderma

Dating back to 1961, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit www.galderma.com

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing, and commercialization of dermatological products. Founded in 1915, Maruho has 1,335 employees (as of the end of September 2015), and net sales were approximately 67.0 billion yen in the previous fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information about Maruho Co., Ltd., please refer to www.maruho.co.jp/english

Contact Information:

Galderma

Yvan Deurbroeck, Global Vice President Communications

Mobile phone +41792543824

Email: yvan.deurbroeck@galderma.com

Maruho Co., Ltd.

Public Relations Department

Shuhei Inokuchi

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-1724

Email: kouhou@mii.maruho.co.jp